Gemini Therapeutics, Inc.

Gemini Therapeutics, Inc. Stock Forecast & Price Prediction

Live Gemini Therapeutics, Inc. Stock (GMTX) Price
$64.78

0

Ratings

  • Buy 0
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$64.78

P/E Ratio

-14.43

Volume Traded Today

$893,560

Dividend

Dividends not available for GMTX

52 Week High/low

77.57/25.61

Gemini Therapeutics, Inc. Market Cap

$519.2M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $GMTX ๐Ÿ›‘

Before you buy GMTX you'll want to see this list of ten stocks that have huge potential. Want to see if GMTX made the cut? Enter your email below

GMTX Summary

From what 0 stock analysts predict, the share price for Gemini Therapeutics, Inc. (GMTX) might decrease by 100% in the next year. This is based on a 12-month average estimation for GMTX. Price targets go from $ to $. The majority of stock analysts believe GMTX is a sell. Please note analyst price targets are not guaranteed and could be missed completely.

GMTX Analyst Ratings

GMTX is a stock in which has been forecasted to be worth $ as an average. On the higher end, the forecast price is $ USD by from Goldman Sachs and on the lower end GMTX is forecasted to be $ by from Goldman Sachs.

GMTX stock forecast by analyst

These are the latest 20 analyst ratings of GMTX.

Analyst/Firm

Rating

Price Target

Change

Date

Andrew Fein
HC Wainwright & Co.

Neutral

$2

Downgrade

Mar 11, 2022
Marc Goodman
SVB Leerink

Market Perform

$2

Downgrade

Mar 3, 2022
Chris Howerton
Jefferies

Hold

$1.5

Downgrade

Mar 1, 2022

SVB Leerink

Outperform

$10

Maintains

Jan 24, 2022
Marc Goodman
SVB Leerink

Outperform

$15

Maintains

Dec 20, 2021

HC Wainwright & Co.

Buy


Initiates

Dec 15, 2021
Graig Suvannavejh
Goldman Sachs

Buy

$18

Maintains

Oct 6, 2021

SVB Leerink

Outperform


Initiates

Apr 8, 2021

Jefferies

Buy


Initiates

Mar 3, 2021

Goldman Sachs

Buy


Initiates

Mar 2, 2021

GMTX Company Information

GMTX
Gemini Therapeutics, Inc. (GMTX)

When did it IPO

2020

Staff Count

0

Country

United States

Sector/Industry

/

CEO

Market Cap

$519.2M

Gemini Therapeutics, Inc. (GMTX) Financial Data

In 2023, GMTX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that GMTX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$0

Revenue From 2021

$0

0.00 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year

Revenue From 2023

N/A

0.00 %
From Previous Year
  • Revenue TTM $0
  • Operating Margin TTM 0.0%
  • Gross profit TTM $0
  • Return on assets TTM -51.2%
  • Return on equity TTM 38.9%
  • Profit Margin 0.0%
  • Book Value Per Share -48.60%
  • Market capitalisation $519.2M
  • Revenue for 2021 $0
  • Revenue for 2022 N/A
  • Revenue for 2023 N/A
  • EPS this year (TTM) $-4.49

Gemini Therapeutics, Inc. (GMTX) Latest News

News Image

Tue, 21 Feb 2023

Sentiment - NEUTRAL

Source - Business Wire

Summary - Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of FS Development Corp., now merged with Gemini Therapeutics (NASDAQ: GMTX), urging them to seek more information.

Why It Matters - The investigation into FS Development Corp. and its merger with Gemini Therapeutics may signal potential legal issues, impacting investor confidence and stock performance for GMTX.

News Image

Tue, 27 Dec 2022

Sentiment - NEUTRAL

Source - PRNewsWire

Summary - Disc Medicine, Inc. received FDA Orphan Drug Designation for bitopertin, aimed at treating erythropoietic protoporphyria (EPP), enhancing its development potential in hematologic diseases.

Why It Matters - Orphan Drug Designation can enhance market exclusivity and financial incentives, potentially increasing Disc Medicine's valuation and attracting investment interest in its pipeline.

News Image

Mon, 21 Nov 2022

Sentiment - POSITIVE

Source - InvestorPlace

Summary - Short-squeeze stocks have gained popularity, involving bets against bearish traders, reflecting a contrarian investment strategy in the current market environment.

Why It Matters - The rise of short-squeeze stocks indicates increased volatility and potential for rapid price movements, signaling opportunities and risks for investors targeting short-term gains.

News Image

Mon, 31 Oct 2022

Sentiment - NEUTRAL

Source - PRNewsWire

Summary - Disc Medicine has initiated the Phase 2 AURORA study to evaluate bitopertin as a treatment for adults with EPP, focusing on safety and efficacy. Top-line data is expected in 2023.

Why It Matters - The AURORA study's results could influence Disc Medicine's stock value, reflecting investor sentiment on the potential success of bitopertin as a treatment for EPP.

News Image

Mon, 26 Sep 2022

Sentiment - NEUTRAL

Source - PRNewsWire

Summary - Halper Sadeh LLC is investigating Gemini Therapeutics, Inc. for potential securities law violations related to its merger with Disc Medicine, Inc., where Gemini shareholders will retain 28% ownership.

Why It Matters - The investigation into Gemini Therapeutics' merger with Disc Medicine raises concerns over potential legal issues and shareholder rights, impacting investor confidence and stock performance.

News Image

Mon, 22 Aug 2022

Sentiment - NEUTRAL

Source - PRNewsWire

Summary - Halper Sadeh LLP is investigating Seacoast Banking Corporation (NASDAQ: SBCF) for potential securities law violations related to its merger with Professional Holding Corp., which involves a stock exchange agreement.

Why It Matters - Investigations into potential securities law violations can indicate risks for shareholders, impacting stock performance and investor confidence in the involved companies.

...

GMTX Frequently asked questions

The highest forecasted price for GMTX is $ from at Goldman Sachs.

The lowest forecasted price for GMTX is $ from from Goldman Sachs

The GMTX analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 0 sell ratings.